Pathogenic Parkinson’s disease mutations across the functional domains of LRRK2 alter the autophagic/lysosomal response to starvation☆

[1]  P. Giunti,et al.  Inhibition of LRRK2 kinase activity stimulates macroautophagy , 2013, Biochimica et biophysica acta.

[2]  A. Mamais,et al.  Phosphorylation of 4E-BP1 in the Mammalian Brain Is Not Altered by LRRK2 Expression or Pathogenic Mutations , 2012, PloS one.

[3]  M. Cookson,et al.  The G2385R variant of leucine-rich repeat kinase 2 associated with Parkinson's disease is a partial loss-of-function mutation. , 2012, The Biochemical journal.

[4]  M. Memo,et al.  Disease-specific phenotypes in dopamine neurons from human iPS-based models of genetic and sporadic Parkinson's disease , 2012, EMBO molecular medicine.

[5]  B. de Strooper,et al.  The mechanism of γ-Secretase dysfunction in familial Alzheimer disease , 2012, The EMBO journal.

[6]  C. Manzoni,et al.  LRRK2 and Human Disease: A Complicated Question or a Question of Complexes? , 2012, Science Signaling.

[7]  G. Churchill,et al.  Leucine-rich repeat kinase 2 regulates autophagy through a calcium-dependent pathway involving NAADP , 2011, Human molecular genetics.

[8]  J. M. Bravo-San Pedro,et al.  The LRRK2 G2019S mutant exacerbates basal autophagy through activation of the MEK/ERK pathway , 2012, Cellular and Molecular Life Sciences.

[9]  H. Cai,et al.  Loss of leucine-rich repeat kinase 2 causes age-dependent bi-phasic alterations of the autophagy pathway , 2012, Molecular Neurodegeneration.

[10]  J. Ioannidis,et al.  Association of LRRK2 exonic variants with susceptibility to Parkinson's disease: a case–control study , 2011, The Lancet Neurology.

[11]  Michael J. Devine,et al.  Pathogenic LRRK2 Mutations Do Not Alter Gene Expression in Cell Model Systems or Human Brain Tissue , 2011, PloS one.

[12]  Y. Liu,et al.  Dopaminergic Neuronal Loss, Reduced Neurite Complexity and Autophagic Abnormalities in Transgenic Mice Expressing G2019S Mutant LRRK2 , 2011, PloS one.

[13]  D. Rubinsztein,et al.  Protein misfolding disorders and macroautophagy , 2011, Current opinion in cell biology.

[14]  Mohamad Saad,et al.  Imputation of sequence variants for identification of genetic risks for Parkinson's disease: a meta-analysis of genome-wide association studies , 2011, The Lancet.

[15]  J. Jankovic,et al.  Preclinical biomarkers of Parkinson disease. , 2011, Archives of neurology.

[16]  V. Baekelandt,et al.  Insight into the mode of action of the LRRK2 Y1699C pathogenic mutant , 2011, Journal of neurochemistry.

[17]  Mark R. Cookson,et al.  The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's disease , 2010, Nature Reviews Neuroscience.

[18]  A. Gitler,et al.  GTPase Activity Plays a Key Role in the Pathobiology of LRRK2 , 2010, PLoS genetics.

[19]  M. Cookson,et al.  The Parkinson's Disease Associated LRRK2 Exhibits Weaker In Vitro Phosphorylation of 4E-BP Compared to Autophosphorylation , 2010, PloS one.

[20]  Richard Wade-Martins,et al.  LRRK2 regulates autophagic activity and localizes to specific membrane microdomains in a novel human genomic reporter cellular model. , 2009, Human molecular genetics.

[21]  A. Whitworth,et al.  Rapamycin activation of 4E-BP prevents parkinsonian dopaminergic neuron loss , 2009, Nature Neuroscience.

[22]  P. Lewis.  The function of ROCO proteins in health and disease , 2009, Biology of the cell.

[23]  M. Cookson,et al.  Leucine-rich repeat kinase 2 mutations and Parkinson’s disease: three questions , 2009, ASN neuro.

[24]  R. Takahashi,et al.  Phosphorylation of 4E‐BP by LRRK2 affects the maintenance of dopaminergic neurons in Drosophila , 2008, The EMBO journal.

[25]  C. Chu,et al.  Role of autophagy in G2019S‐LRRK2‐associated neurite shortening in differentiated SH‐SY5Y cells , 2008, Journal of neurochemistry.

[26]  C. Olanow,et al.  Leucine‐rich repeat kinase 2 (LRRK2)/PARK8 possesses GTPase activity that is altered in familial Parkinson’s disease R1441C/G mutants , 2007, Journal of neurochemistry.

[27]  M. Cookson,et al.  The R1441C mutation of LRRK2 disrupts GTP hydrolysis. , 2007, Biochemical and biophysical research communications.

[28]  I. Marín.  The Parkinson disease gene LRRK2: evolutionary and structural insights. , 2006, Molecular biology and evolution.

[29]  C. Ross,et al.  Kinase activity of mutant LRRK2 mediates neuronal toxicity , 2006, Nature Neuroscience.

[30]  David W. Miller,et al.  Kinase activity is required for the toxic effects of mutant LRRK2/dardarin , 2006, Neurobiology of Disease.

[31]  C. Ross,et al.  Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[32]  J. Hardy,et al.  Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. , 1996, Nature medicine.